A PYMNTS Company

Illumina Agrees Buy Cancer Startup Grail For $8B

By  |  September 21, 2020

Genetic sequencing biotech Illumina has agreed to acquire Grail, the cancer screening start-up backed by Jeff Bezos and Bill Gates, in an US$8 billion cash-and-stock deal that will be its largest to date, reported The Financial Times. 

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Grail specializes in the emerging field of liquid biopsy: taking a blood sample to test for cancer. By detecting tumour DNA in the bloodstream, the technology can identify more than 50 cancers, including where they are located in the body, with a false positive rate of less than 1%. 

    The aim is to develop a product that will detect cancers early and in a less intrusive way than traditional biopsies, which involve taking a tissue sample. 

    However, creating such a product takes time, as there are risks of false alarms when people without symptoms are tested. The company’s test is still in very large trials — including one with 100,000 participants. Last year, it received a breakthrough designation from the US Food and Drug Administration, which aims to accelerate the review of new products.